| scholarly article | Q13442814 |
| P2093 | author name string | Zhigang Xie | |
| Jayantha Gunaratne | |||
| Gaofeng Huang | |||
| Shaw Cheng Liu | |||
| Wee Joo Chng | |||
| Lip Lee Cheong | |||
| Walter P Blackstock | |||
| Tze Loong Koh | |||
| P2860 | cites work | Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family | Q24291883 |
| Multiple myeloma | Q24655964 | ||
| The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor | Q40031496 | ||
| Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells | Q40399386 | ||
| p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis | Q40579357 | ||
| Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. | Q41087450 | ||
| A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. | Q51547306 | ||
| A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. | Q52858755 | ||
| Functional and quantitative proteomics using SILAC | Q57369727 | ||
| Multiple myeloma | Q77292034 | ||
| In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression | Q78410148 | ||
| Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients | Q24670250 | ||
| A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription | Q28142350 | ||
| Chromosome translocations in multiple myeloma | Q28199347 | ||
| A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript | Q28214995 | ||
| The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts | Q28286552 | ||
| Strategies for silencing human disease using RNA interference | Q28288535 | ||
| A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC) | Q28296386 | ||
| MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification | Q29547200 | ||
| In-gel digestion for mass spectrometric characterization of proteins and proteomes | Q29547583 | ||
| Drug-target network | Q29614447 | ||
| Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs | Q31112284 | ||
| SLAM-family receptors: immune regulators with or without SAP-family adaptors | Q33693795 | ||
| Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells | Q33948015 | ||
| Cloning, genomic organization, alternative transcripts and expression analysis of CD99L2 , a novel paralog of human CD99, and identification of evolutionary conserved motifs | Q34191933 | ||
| Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. | Q34210005 | ||
| Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. | Q34328725 | ||
| The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. | Q34568855 | ||
| Membrane proteins and membrane proteomics | Q34657071 | ||
| CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes | Q34689964 | ||
| Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma | Q35170921 | ||
| Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression | Q35568362 | ||
| CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma | Q35610286 | ||
| Molecular pathogenesis and a consequent classification of multiple myeloma | Q36254602 | ||
| The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. | Q36384699 | ||
| NK cell regulation by SLAM family receptors and SAP-related adapters | Q36652149 | ||
| Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. | Q36654607 | ||
| Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu | Q36835070 | ||
| Targeted delivery of small interfering RNA: approaching effective cancer therapies | Q37100611 | ||
| Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery | Q37119996 | ||
| Membrane-tethered proteins for basic research, imaging, and therapy. | Q37164168 | ||
| IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes | Q37238620 | ||
| Characterization of MYC translocations in multiple myeloma cell lines | Q37331601 | ||
| Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma | Q37357340 | ||
| Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model | Q39865719 | ||
| MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. | Q39908262 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| overexpression | Q61643320 | ||
| P304 | page(s) | 1008-1018 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma | |
| P478 | volume | 4 |
| Q58582611 | Clinical impact of serum soluble SLAMF7 in multiple myeloma |
| Q55310350 | Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling. |
| Q48169937 | Immunopathogenesis and immunotherapy of multiple myeloma. |
| Q92014013 | Immunotherapy for Multiple Myeloma |
| Q47626310 | Integrated powered density: Screening ultrahigh dimensional covariates with survival outcomes. |
| Q93336711 | MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells |
| Q38850840 | MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib |
| Q33908640 | MMSET: role and therapeutic opportunities in multiple myeloma. |
| Q59136966 | Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma |
| Q91814085 | Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia |
| Q89565340 | Molecular basis of clonal evolution in multiple myeloma |
| Q92266478 | Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7 |
| Q28076147 | Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date |
| Q40968068 | Streamlined Membrane Proteome Preparation for Shotgun Proteomics Analysis with Triton X-100 Cloud Point Extraction and Nanodiamond Solid Phase Extraction |
| Q36169794 | The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy |
Search more.